United Kingdom: Intellectual Property

Generative AI tools are making it easier than ever to inadvertently infringe intellectual property rights, from copying album artwork to replicating entire business websites. What legal risks emerge when AI crosses the line into IP infringement, and how should businesses building or deploying AI-generated outputs protect themselves?

How is artificial intelligence transforming the creative industries, and what skills will designers need to thrive in an AI-driven future? Industry experts from tangerine, terrible*, The Frank Co., and Cleo explore the evolving relationship between AI, sustainability, and human-centered design in this thought-provoking discussion recorded at the London Design Festival.

An intellectual property lawyer helps businesses protect, register, commercialise and enforce their ideas, brands, products and creative assets. Good advice works in two directions: it helps a business stay on the right side of existing rights and avoid attracting claims, while also shaping its own portfolio so it becomes defensible, valuable and enforceable.

An organisation's brand is one of its most valuable assets, yet many fail to protect it adequately through trade mark registration. This comprehensive guide explores how to build and manage an effective trade mark portfolio, from initial clearance searches and strategic filing decisions to ongoing monitoring, enforcement and licensing arrangements that preserve brand value over the long term.

Developing effective crop protection patents in Europe requires navigating complex challenges involving chemistry, biology, regulation and commercial strategy. From establishing inventive step for novel active ingredients to protecting formulations and synergistic combinations, agrochemical innovators must consider multiple layers of patent protection that align with lengthy regulatory timelines and evolving market needs.

FIFA has launched three innovation challenges targeting fan experience enhancement, advanced player wearables for real-time physiological monitoring, and automated substitution board technology. The initiatives reveal the governing body's strategic priorities in modernizing football through technology while maintaining creator IP ownership and establishing structured pathways from prototype to global implementation.

Generative AI tools are making it easier than ever to inadvertently infringe intellectual property rights, from copying album artwork to replicating entire business websites. What legal risks emerge when AI crosses the line into IP infringement, and how should businesses building or deploying AI-generated outputs protect themselves?

The Supreme Court's decision in Emotional Perception AI has reshaped how software inventions are examined at the UKIPO, aligning UK practice with the EPO's approach. A recent hearing demonstrates that while determining eligibility may be straightforward, assessing which features possess technical character presents significant challenges that can fundamentally impact the inventive step analysis.

Developing effective crop protection patents in Europe requires navigating complex challenges involving chemistry, biology, regulation and commercial strategy. From establishing inventive step for novel active ingredients to protecting formulations and synergistic combinations, agrochemical innovators must consider multiple layers of patent protection that align with lengthy regulatory timelines and evolving market needs.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

As computational biology and artificial intelligence reshape drug discovery, pharmaceutical companies face a critical challenge: how to protect not just the final therapeutic compound, but the entire ecosystem of datasets, models, and biological insights that enabled its creation. This article examines the evolving intellectual property landscape where 90% of clinical candidates still fail, yet the tools predicting their success are becoming as valuable as the medicines themselves.

The European Health Data Space (EHDS) regulation has entered into force, creating a harmonised framework for cross-border health data access across the EU. While Europe possesses exceptional health data resources—particularly in Nordic countries with comprehensive patient registries—it has historically lacked the commercial data market infrastructure seen in the United States. This analysis explores how life science companies and investors can position themselves to capitalise on emerging opport